Related Experiment Video

Updated: Jun 3, 2026

Ultra-Fast Amplicon-Based Next-Generation Sequencing in Non-Squamous Non-Small Cell Lung Cancer
07:59

Ultra-Fast Amplicon-Based Next-Generation Sequencing in Non-Squamous Non-Small Cell Lung Cancer

Published on: September 8, 2023

New targets in advanced NSCLC: EML4-ALK

Adam S Crystal1, Alice T Shaw

  • 1Massachusetts General Hospital Cancer Center Center, Boston, MA 02114, USA.

Clinical Advances in Hematology & Oncology : H&O
|April 9, 2011
PubMed

Insights

The EML4-ALK fusion gene drives certain lung cancers. ALK inhibitors like crizotinib show promise for treating these specific cancers, with new diagnostics and trials underway.

Area of Science:

  • Oncology
  • Molecular Biology
  • Pharmacology

Background:

  • Targeted therapies inhibiting oncogenic tyrosine kinases are crucial in cancer treatment.
  • The EML4-ALK fusion gene, identified in 2007, is a key oncogenic driver in non-small cell lung cancer.
  • ALK rearrangements represent a significant subset of lung cancer drivers.

Purpose of the Study:

  • To review the discovery and implications of the EML4-ALK fusion gene.
  • To discuss the development of diagnostic tools for ALK rearrangements.
  • To summarize the clinical epidemiology and ongoing therapeutic strategies for ALK-driven lung cancers.

Main Methods:

  • Literature review of EML4-ALK discovery.
  • Analysis of clinical diagnostic development for ALK rearrangements.
  • Review of epidemiological data for ALK-rearranged lung cancers.
  • Survey of ongoing clinical trials involving ALK inhibitors.

Main Results:

  • The EML4-ALK fusion gene is a validated oncogenic driver in a subset of non-small cell lung cancers.
  • Clinical diagnostics for detecting ALK rearrangements have been successfully developed.
  • ALK inhibitors, such as crizotinib, are demonstrating significant clinical efficacy.
  • Numerous clinical trials are evaluating the effectiveness of ALK inhibitors.

Conclusions:

  • EML4-ALK fusion represents a critical target for precision cancer medicine.
  • Diagnostic advancements enable patient stratification for targeted therapy.
  • ALK inhibitors offer a new paradigm for treating ALK-rearranged lung cancers.
  • Further clinical trials are essential to optimize ALK inhibitor-based treatment strategies.

More Related Videos

Oncogenic Gene Fusion Detection Using Anchored Multiplex Polymerase Chain Reaction Followed by Next Generation Sequencing09:49

Oncogenic Gene Fusion Detection Using Anchored Multiplex Polymerase Chain Reaction Followed by Next Generation Sequencing

Published on: July 5, 2019

Exosomal miRNA Analysis in Non-small Cell Lung Cancer (NSCLC) Patients' Plasma Through qPCR: A Feasible Liquid Biopsy Tool08:49

Exosomal miRNA Analysis in Non-small Cell Lung Cancer (NSCLC) Patients' Plasma Through qPCR: A Feasible Liquid Biopsy Tool

Published on: May 27, 2016

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase01:11

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...